Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.48 |
| ▸ | RBP4 | P02753 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3320963 | 0.90 | HSD11B1 (0.57) | HSD11B1GAATRPA1RBP4POLB | |
| SCHEMBL3669452 | 0.85 | GAA (0.50) | HSD11B1GAATRPA1TRPV1ALDH1A1 | |
| SCHEMBL3322414 | 0.81 | EPHX2 (0.61) | ALDH1A1 | |
| SCHEMBL3320758 | 0.81 | ALDH1A1 (0.45) | HSD11B1ALDH1A1SLC6A7 | |
| SCHEMBL3095680 | 0.79 | HSD11B1 (0.76) | HSD11B1GAATRPA1RBP4TRPV1 | |
| SCHEMBL3320915 | 0.77 | SMO (0.51) | HSD11B1POLBALDH1A1SLC6A7 | |
| SCHEMBL3673302 | 0.75 | TRPV1 (0.52) | HSD11B1GAATRPA1RBP4POLB | |
| SCHEMBL3319306 | 0.72 | MAPT (0.47) | ALDH1A1SLC6A7 | |
| SCHEMBL9961691 | 0.72 | CNR1 (0.42) | HSD11B1GAAPOLBALDH1A1 | |
| Hydrochloric Acid SCHEMBL3319163 | 0.71 | CNR1 (0.42) | HSD11B1GAAPOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2155717-B1 | 2-[4-(PYRAZOL-4-YLALKYL)PIPERAZIN-1-YL]-3-PHENYL PYRAZINES AND PYRIDINES AND 3-[4-(PYRAZOL-4-YLALKYL)PIPERAZIN-1-YL]-2-PHENYL PYRIDINES AS 5-HT7 RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2012-10-24 | — | — | EP | disclosed |
| US-20100120785-A1 | 2-[4-(PYRAZOL-4-YLALKYL)PIPERAZIN-1-YL]-3-PHENYL PYRAZINES AND PYRIDINES AND 3-[4-(PYRAZOL-4-YLALKYL)PIPERAZIN-1-YL]-2-PHENYL PYRIDINES AS 5-HT7 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120785-A1 | 2-[4-(PYRAZOL-4-YLALKYL)PIPERAZIN-1-YL]-3-PHENYL PYRAZINES AND PYRIDINES AND 3-[4-(PYRAZOL-4-YLALKYL)PIPERAZIN-1-YL]-2-PHENYL PYRIDINES AS 5-HT7 RECEPTOR ANTAGONISTS | HTR7, HTR2C, HTR4 | HSD11B1 3026/4885GAA 4789/4885TRPA1 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.